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Economic EvaluationHigh-Dose Hemodialysis versus Conventional In-Center
Hemodialysis: A Cost-Utility Analysis from a UK
Payer Perspective
Frank Xiaoqing Liu, PhD1,*, Catrin Treharne, MSc2, Murat Arici, MBA3, Lydia Crowe, MSc2,
Bruce Culleton, MD1
1Baxter Healthcare Corporation, Deerﬁeld, IL, USA; 2Abacus International, Oxfordshire, UK; 3Baxter International UK, Compton, UKA B S T R A C TObjective: To investigate the cost-effectiveness of high-dose hemo-
dialysis (HD) versus conventional in-center HD (ICHD), over a lifetime
time horizon from the UK payer’s perspective. Methods: We used a
Markov modeling approach to compare high-dose HD (in-center or at
home) with conventional ICHD using current and hypothetical home
HD reimbursement tariffs in England. Sensitivity analyses tested the
robustness of the results. The main outcome measure was the
incremental cost-effectiveness ratio (ICER) expressed as a cost per
quality-adjusted life-year (QALY). Results: Over a lifetime, high-dose
HD in-center (5 sessions/wk) is associated with higher per-patient
costs and QALYs (increases of £108,713 and 0.862, respectively) versus
conventional ICHD. The corresponding ICER (£126,106/QALY) indicates
that high-dose HD in-center is not cost-effective versus conventional
ICHD at a UK willingness-to-pay threshold of £20,000 to £30,000. High-
dose HD at home is associated with lower total costs (£522 less per
patient) and a per-patient QALY increase of 1.273 compared with ICHDee front matter Copyright & 2015, International S
r Inc. This is an open access article under the CC
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At an increased home HD tariff (£575/wk), the ICER for high-dose HD
at home versus conventional ICHD is £17,404/QALY. High-dose HD at
home had a 62% to 84% probability of being cost-effective at a
willingness-to-pay threshold of £20,000 to £30,000/QALY. Conclusions:
Although high-dose HD has the potential to offer improved clinical and
quality-of-life outcomes over conventional ICHD, under the current UK
Payment-by Results reimbursement scheme, it would be considered cost-
effective from a UK payer perspective only if conducted at home.
Keywords: cost-effectiveness analysis, cost-utility analysis, end-stage
renal disease, high-dose hemodialysis, in-center hemodialysis.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
End-stage renal disease (ESRD) is an irreversible decline in kidney
function that, without dialysis or kidney transplantation (renal
replacement therapy [RRT]), is fatal. In the United Kingdom and
globally, ESRD poses a substantial health and economic burden.
In 2009-2010, the England National Health Service (NHS) spent an
estimated £1.45 billion (1.3% of all NHS spending) on chronic
kidney disease. Half this amount was spent providing RRT to
patients with ESRD even though patients receiving RRT represent
only 2% of the population with chronic kidney disease [1].The two main dialysis modalities are hemodialysis (HD) and
peritoneal dialysis (PD). HD is generally performed in a hospital or
satellite unit but can be performed at home in suitable patients
(home hemodialysis [home HD]). In the United Kingdom, 80% of
prevalent dialysis patients receive conventional HD, usually 3
sessions/wk and 3 to 5 hours a session [2]. Evidence suggests,
however, that clinical and quality-of-life (QOL) outcomes can be
improved with higher doses of HD by increasing the frequency
and/or duration of treatment via short-daily, quotidian or noctur-
nal HD. Three randomized controlled trials reported that frequent
nocturnal HD and six times weekly in-center HD (ICHD) wereociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 7 – 2 418associated with clinically signiﬁcant improvements in selected
clinical and QOL measures versus conventional, thrice-weekly HD
[3–5]. Several observational and retrospective studies reported 36%
to 61% reductions in mortality in patients receiving high-dose HD
versus conventional HD [6–8]. Home HD has further beneﬁts:
patients have greater control over their dialysis schedule, fewer
travel requirements, and are less exposed to hospital pathogens [9].
Previously published cost-effectiveness analyses of high-dose
HD versus conventional ICHD are based on earlier evidence.
Recent clinical and humanistic evidence warrants a reevaluation
of the cost-effectiveness of high-dose HD. Although an earlier NHS
analysis showed that home HD was associated with lower costs
and better outcomes than was ICHD, increased dialysis frequency,
duration, or both were not included in its main evaluation [10]. A
2003 National Institute for Health and Care Excellence (NICE)
appraisal of home HD considered the cost-effectiveness of short-
daily and nocturnal home HD, but only in sensitivity analysis [9].
The current analysis assesses the cost-effectiveness of high-dose
HD (in-center or at home) versus conventional ICHD over a lifetime
time horizon from a UK payer perspective. Given the average age
of the home HD population in the United Kingdom (47–48 years
old), a time horizon of 40 years is used and believed to be
equivalent to a lifetime time horizon for patients with ESRD.Methods
We constructed a Markov model to assess the cost-effectiveness
of high-dose HD performed in-center or at home compared with
thrice-weekly, conventional ICHD by simulating a hypothetical
adult ESRD population requiring RRT. Model structure and data
inputs were informed by a review of literature and renal registry
reports.Model Structure
The model comprises a number of discrete health states between
which patients can move (Fig. 1) and adopts 28-day cycles to
ensure consistency in calculations. Short cycles are preferable in
ESRD because of their sensitivity to likely changes in health states
[10,11]. From one cycle to the next, the patients may stay on their
current modality, change modality, undergo a kidney transplant,
or die (in any health state). To reﬂect clinical practice, patients may
move to PD or kidney transplant during the model time horizon.High dose HD
(in-centre or home) 
Complications Transp
Post-tran
PD
Complica
Fig. 1 – Model ﬂow diagram. Each dialysis modality is shown as
in-center hemodialysis (ICHD) includes hospital or satellite; hig
transplant; posttransplant. Patients can die from any of the healt
is the comparison of costs and outcomes between patients on hig
patients may move to PD during the model time horizon.Model Inputs
Model inputs were sourced from published articles, UK Renal
Registry annual reports, NHS Payment-by-Results (PbR) tariffs,
and the European Renal Association-European Renal Dialysis and
Transplant Association (ERA-EDTA) registry report.Quality of Life
Patients’ QOL has been shown to vary between dialysis modal-
ities. A systematic review by Liem et al. [12] provides the main
source of utilities for the model with adjustments to account for
the improved QOL in patients receiving high-dose HD and for the
home setting (Table 1). Culleton et al. [4] is the only randomized
controlled trial to have considered the effect of dialysis dose on
patient utility, demonstrating a 17.6% increase in utility from
baseline in patients changing from conventional ICHD to high-
dose HD at home. We assumed that half this beneﬁt comes from
the change to high-dose HD and half from the move to the home
setting; consequently, in the model, patients receiving high-dose
HD have utility values 8.8% higher than the utility values of those
receiving conventional HD. Considering that the assumption is
based on one small study, we varied the percentages of beneﬁt in
sensitivity analysis. De Wit et al. [13] reported 22.7% higher QOL
values for patients on limited care HD than for patients on ICHD
(0.81 vs. 0.66). The ratio of these values was applied to the utility
assigned to patients on ICHD (from Liem et al. [12]) to derive the
utility for patients receiving conventional home HD, assuming that
the QOL of patients receiving limited care HD in the De Wit et al.
study is comparable to that of conventional home HD patients.Survival
Survival of patients receiving conventional HD in the model is
estimated using survival data for European incident patients on
HD published in the ERA-EDTA 2009 Annual Report [14]. Use of
ERA-EDTA data requires us to assume that these patients are
representative of those in the United Kingdom (in the ERA-EDTA
2009 Annual Report, UK patients represent 20% of all incident
patient counts). Parametric survival models were ﬁtted to 5-year
survival data to extrapolate beyond 5 years [15]. An exponential
distribution provided the best ﬁt for HD survival data based on a
comparison of Akaike information criterion values (the model
with the smallest Akaike information criterion value is preferred).Conventional
ICHD
Complicationslant
splant
tions
a separate health state in the model as follows: conventional
h-dose HD, in-center or at home; peritoneal dialysis (PD);
h states in the model. Although the emphasis of the analysis
h-dose and conventional HD, to reﬂect clinical practice some
Table 1 – Clinical and QOL parameters and cost elements applied in the model.
Clinical and QOL parameters
Parameter Value (range*) and parameter distribution† Data sources
Mortality
High-dose HD mortality HR vs. conventional HD 0.76 (0.57–0.95), lognormal [7,8,17]
Utilities
QOL improvement for high-dose HD 8.8% (6.6%–11.0%), beta [4]
Conventional ICHD utility 0.56 (0.49–0.62), beta [12]
High-dose ICHD utility 0.61, beta [4,12]
Conventional home HD utility 0.69 (0.52–0.86), beta [12,13]
High-dose home HD utility 0.75, beta [4]
Transplant/posttransplant utility 0.81 (0.72–0.90), beta [12]
Hospitalizations (%)
Conventional ICHD hospitalization probability (28 d)
First year 7.05 (5.29–8.81), beta [3]
Subsequent years 4.86 (3.65–6.08), beta [20]
High-dose ICHD hospitalization probability (28 d)
First year 6.49 (4.87–8.11), beta [3]
Subsequent years 4.48 (3.36–5.60), beta [20]
Conventional home HD hospitalization probability (28 d)
First year 5.35 (4.01–6.68), beta [5]
Subsequent years 3.69 (2.77–4.61), beta [20]
High-dose home HD hospitalization probability (28 d)
First year 7.09 (5.32–8.86), beta [5]
Subsequent years 4.89 (3.67–6.11), beta [20]
Transplant probabilities
Transplant rate for all modalities (28 d) 0.007 (0.005–0.009), beta [18,22,45]
Graft failure probability for all modalities (28 d) 0.004 (0.003–0.005), beta [18]
Transition probabilities (%)
Proportion moving from ICHD to home HD (28 d)
0–6 mo and 7–12 mo 0.05 (0.04–0.06), beta Assumption
13–18 mo 0.03 (0.02–0.04), beta
19þ mo 0
Proportion moving from home HD to ICHD (28 d)
Constant probability 0.38 (0.29–0.48), beta [33]
Cost elements
Parameter Value (range‡) Data sources
Access costs—initial access and access maintenance due to technique failure or access failure (£)
Vascular access cost 1,287 (965–1,609) [21]
Dialysis services cost
ICHD cost per session§ 147 [21,46]
Home HD cost per week 456 (342–570) [21]
ESA costs
ESA cost per 1000 units 5.09 (3.82–6.36) [47]
Conventional ICHD and home HD ESA dose (units/wk) 6705 (5029–8381) [48]
High-dose ICHD ESA dose (units/wk) 5280 (3960–6600) [3,48]
Monitoring costs (£)
Annual monitoring cost for all patients|| 380 [21]
Hospitalization costs (£)
Cost per (HD) hospitalization¶ 1,904 (1,428– 2,380) [21,23]
Transport cost per visit (applied only to ICHD sessions) (£)
Weighted# 46 (34–57) [24–26,29]
Transplant and posttransplant costs (£)
Procedure cost** 18,579 [18,27]
Posttransplant medication cost (annual) 11,137 (8,352–13,921) [49]
Note. The clinical and cost inputs associated with PD were included in Appendix Table 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.jval.2014.10.002).
AV, arteriovenous; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; HR, hazard ratio; ICHD, in-center hemodialysis; NHS, National
Health Service; PbR, Payment-by Results; PSA, probabilistic sensitivity analysis; QOL, quality of life.
* Variables were varied according to published ranges (95% conﬁdence intervals) or by 25% for those variables without such information.
† The distributions selected are widely believed to be appropriate choices for the model parameters and reﬂect best practice.
‡ For PSA, all cost inputs are assumed to follow a gamma distribution; this reﬂects best practice.
§ The overall ICHD cost per session is based on a weighted average of catheter access and AV ﬁstula/graft access tariffs, £121 (£91–£151) and
£152 (£114–£190), respectively. The breakdown is based on the target percentage set by the best practice tariff for 2013–2014.
|| Patients on each modality are assumed to receive two monitoring visits a year. The cost of a monitoring visit is calculated as the average of a
single professional visit cost, £132 (£99–£165), and a multiprofessional visit cost, £247 (£185–£309).
¶ A weighted average HD hospitalization cost was calculated on the basis of costs from the PbR tariff 2013–2014 and event numbers from the
National Schedule of Reference Costs 2011–2012.
# A weighted transport cost per ICHD visit was calculated on the basis of the following cost elements: ambulance service vehicle, £189;
hospital-provided car, £27; hospital-arranged taxi, £31; hospital transport vehicle, £13; public and private transport, £5. Proportions are based
on the National Kidney Care Audit, Patient Transport Survey from 2010.
** The overall transplant cost is based on a weighted average of costs of transplant from the following donors: donor after brain death, £19,804
(£14,853–£24,755); donor after cardiac death, £16,580 (£12,435–£20,725); living donor, £18,640 (£13,980–£23,300). Proportions based on data
from the NHS Blood and Transplant Activity Report for 2012–2013.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 7 – 2 420Several observational studies reported differences in survival
between patients treated with high-dose HD versus conventional
HD [6–8,16,17]. In our base-case analysis, we assumed an overall
mortality hazard ratio of 0.76 for high-dose HD versus conven-
tional HD up to 10 years, based on the literature (Table 1) [7,8,17].
This was calculated as each study’s reported mortality hazard
ratio weighted by its relative treatment group size. Because of
lack of long-term data, patients receiving high-dose and conven-
tional HD are subject to equal mortality rates beyond 10 years.
Following kidney transplant, patient survival is modeled using
data from the NHS Blood and Transplant Activity Report for 2012-
2013 [18]. If graft failure occurs, survival is again modeled
according to dialysis modality.
Dialysis Session Frequency and Duration
As recommended by the UK Renal Association [19], the model
assumes that conventional ICHD comprises 3 sessions/wk. In the
main analysis, high-dose HD is deﬁned as 5 sessions/wk. Session
frequency is varied in scenario analyses.
Transition Probabilities
Patients may be treated with various dialysis modalities during
their time on RRT and may move from ICHD to home HD and vice
versa (Table 1). To reﬂect clinical practice, patients may get
kidney transplantation or move to PD. In the event of graft
failure, patients return to their original HD setting.
Dialysis Complications: All-Cause Hospitalizations
Patients may experience complications while undergoing dialy-
sis, resulting in hospitalization. All-cause hospitalizations in the
ﬁrst year are sourced from the Frequent Haemodialysis Network
publications (Table 1) [3,5]. Hospitalization rates in subsequent
years were estimated via a ratio of ﬁrst year to subsequent year
hospitalizations using data from Arora et al. [20].
Costs
Given the UK NHS payer perspective, the model uses Payment-by-
Results (PbR) tariffs to approximate costs of providing RRT to
patients with ESRD. In England, dialysis services are funded by the
NHS as a payer on behalf of the Department of Health using the PbR
system, a national tariff of ﬁxed prices reﬂecting national average
costs of hospital procedures with data gathered from all NHS
hospitals. Tariffs for HD are based on the care setting (hospital,
satellite unit, or home) and vascular access. ICHD reimbursement is
on a per-session basis to account for staff costs and consumables.
Home HD currently has a ﬁxed weekly tariff intended to cover initial
training and home modiﬁcation costs and designed to enable the
provider to recover the upfront investment over time. The home HD
tariff also covers home care visits and machine maintenance costs.
The model considers cost elements associated with ESRD treatment,
including dialysis access establishment and maintenance [21],
dialysis service [21], erythropoiesis-stimulating agents (not included
in the tariff prices) [22], all-cause hospitalizations [21,23], patient
monitoring [21], transportation to/from clinics [24–26], and kidney
transplantation and maintenance [27] (Table 1).
Cost-Effectiveness Analysis
For base-case analyses, high-dose HD comprises 5 sessions/wk. In
each analysis, the reference scenario consists of all the patients
commencing conventional ICHD; alternative scenarios assume
that all the patients start on high-dose HD (in-center or at home).
The current home HD tariff is set equal to three ICHD reimburse-
ment tariffs per week [28], which provides little incentive for
providers to increase the use of home dialysis, especially high-doseHD at home. To be consistent with the reimbursement mechanism
for high-dose HD in-center, in addition to the existing ﬁxed home HD
tariff, we used 5 times the 2010-2011 reference costs for a home HD
session (£115/session, £575/wk) as cost input to assess the cost-
effectiveness of high-dose HD at home versus conventional ICHD [29].
In line with UK Treasury guidance, future costs and beneﬁts
were discounted at 3.5% per annum [30]. The main outcome
measure was the incremental cost-effectiveness ratio (ICER), the
cost per incremental quality-adjusted life-year (QALY).
Scenario Analysis
An additional scenario analysis was conducted in which the
number of sessions per week for patients receiving high-dose
HD in-center was varied to 3.5 sessions/wk (alternative nights;
the minimal number of treatments per week necessary to avoid
the 2-day gap in therapy [31]) because this best corresponds to
regimens used in studies showing optimal outcomes [6,8,16,17].
In addition, because observational, nonrandomised data are used
to calculate the survival beneﬁt for high-dose HD versus conven-
tional ICHD, the assumption of improved survival is tested by
assuming no difference. For the in-center comparisons, the
survival assumption scenario is reported for the 5 sessions/wk
regimen only.
Sensitivity Analyses
One-way sensitivity analysis was conducted by replacing the
base-case value of each model parameter in turn with its lowest
and highest plausible values (published ranges or 25% for
variables without such information). Published conﬁdence inter-
vals were available for transplant graft failure rates [18] and
utility values from the Liem et al. [12] study. Changes recorded in
the net beneﬁt value are presented as a tornado diagram. The net
beneﬁt value is calculated by subtracting incremental costs from
the monetary value of incremental QALYs achieved based on the
current UK willingness-to-pay (WTP) value. A positive net beneﬁt
value indicates that health gains exceed the incremental cost and
the intervention is considered cost-effective; a negative value
implies that it is not cost-effective.
Probabilistic sensitivity analysis was also performed, in which
model parameters are varied according to appropriate statistical
distributions reﬂecting best practice (Table 1). The effect of
parameter uncertainty on model results can be considered by
running a large number of simulations. Results are presented as a
cost-effectiveness plane scatter diagram and a cost-effectiveness
acceptability curve, which presents the probability that an inter-
vention would be deemed cost-effective versus the comparator at
different values of the WTP threshold.Results
Is High-Dose HD Cost-Effective When Performed In-Center?
For the reference scenario (100% conventional ICHD), total life-
time discounted costs and QALYs per patient are £191,207 and
5.267, respectively (Table 2). High-dose HD in-center is associated
with higher costs (an increase of £108,713 per patient) and more
QALYs (an increase of 0.862 per patient) compared with conven-
tional ICHD. The ICER for high-dose HD in-center versus conven-
tional ICHD is £126,106; at the perceived NICE WTP threshold of
£20,000 to £30,000 per QALY, it is not cost-effective.
The ICER for high-dose HD (3.5 sessions/wk) is £50,598, also
higher than the perceived NICE WTP threshold. When high-dose
HD in-center is 5 sessions/wk but no survival beneﬁt is assumed,
total costs are relatively lower, given the reduction in survival,
but the overall ICER is much higher at £396,614.
Table 2 – Head-to-head comparison of conventional ICHD and high-dose HD in-center.
Comparative scenario analyses Total costs (£) QALYs ICER (vs. reference scenario)
(£)
Reference scenario: 100% conventional ICHD 191,207 5.267 –
100% high-dose ICHD, 5 sessions/ wk 299,920 6.129 126,106
Scenario analyses Total costs (£) QALYs ICER (vs. reference scenario)
100% high-dose ICHD, 3.5 sessions/ wk 234,826 6.129 50,598
Reference scenario: 100% conventional ICHD, no difference in
survival
191,160 5.265 –
100% high-dose ICHD, 5 sessions/wk, no difference in survival 265,802 5.453 396,614
HD, hemodialysis; ICER, incremental cost-effectiveness ratio; ICHD, in-center hemodialysis; QALY, quality-adjusted life-year.
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across the main comparison and scenario analyses, we present
results for high-dose HD in-center (5 sessions/wk) versus conven-
tional ICHD (3 sessions/wk). Cost and frequency of HD sessions
have the greatest impact on net beneﬁt (Fig. 2A). A higher number
of HD sessions per week, or a higher tariff for those sessions, is-120K             -110K             -100K              -90K               -80
HD median survival (years) 5.02 (3.06 - 8.24)
Hospital (AV Fistula/Graft) high dose reimbursement £152 (£114 - £190)
Number of sessions per week for Hospital high dose 5 (4 - 6)
Number of sessions per week for Hospital conventional 3 (2 - 4)
Sat / low care (AV Fistula/Graft) high dose reimbursement 152 (114 - 190)
Number of sessions per week for Sat / low care high dose 5 (4 - 6)
Number of sessions per week for Sat / low care conventional 3 (2 - 4)
Incident vs prevalent HR 1.06 (0.80 - 1.33)
Mortality HR vs 2000 cohort of patients 1 (0.75 - 1.25)
Hospital (AV Fistula/Graft) conventional reimbursement £152 (£114 - £190)
Mortality HR for high dose vs conventional - year 4-10 0.76 (0.57 - 0.95)
Sat / low care (AV Fistula/Graft) conventional reimbursement £152 (£114 - £190)
Discount rate costs 3.5% (2.6% - 4.4%)
Transportation cost (single value) £46 (£34 - £57)
Annual rate 9% (7% - 11%)
Net benefit (£) 
-20K   -15K   -10K    -5K        0         5K     10K    15
Home HD (AV Fistula/Graft) high dose reimbursement £575 (£431 - £719) 
Number of sessions per week for Hospital conventional 3 (2 - 4) 
Conventional home HD utility - Assumption 0.69 (0.52 - 0.86) 
Number of sessions per week for Sat / low care conventional 3 (2 - 4) 
Hospital (AV Fistula/Graft) conventional reimbursement £152 (£114 - £190) 
Sat / low care (AV Fistula/Graft) conventional reimbursement £152 (£114 - £190) 
Transportation cost (single value) £46 (£34 - £57) 
Home HD (Catheter) high dose reimbursement £575 (£431 - £719) 
HD median survival (years) 5.02 (3.06 - 8.24) 
Mortality HR for high dose vs conventional - year 4-10 0.76 (0.57 - 0.95) 
Conventional ICHD Hospital utility - Liem 0.56 (0.49 - 0.62) 
Mortality HR for high dose vs conventional - year 1 0.76 (0.57 - 0.95) 
Disount rate outcomes 3.5% (2.6% - 4.4%) 
Discount rate costs 3.5% (2.6% - 4.4%) 
Incident vs prevalent HR 1.06 (0.80 - 1.33) 
Net benefit (£) 
Fig. 2 – One-way and probabilistic sensitivity analyses of high-d
(increased tariff, £575/wk) vs. conventional ICHD, WTP threshold
tornado diagram (A) shows the sensitivity of the net beneﬁt to ch
impact on the net beneﬁt are shown by the biggest bars at the to
impact are shown at the bottom. The cost and frequency of ICHD
The CEAC (B) shows that the probability that high-dose HD in-ce
of the WTP threshold (£0–£75,000). For high-dose HD at home at
biggest drivers of the results are the weekly tariff and the utility
high-dose HD at home is cost-effective is 61.8% at £20,000 and 8
HD, hemodialysis; HR, hazard ratio; ICHD, in-center hemodialys
WTP, willingness to pay.associated with a lower net beneﬁt. HD survival parameters were
also important drivers of model results. None of the univariate
parameter changes results in a positive net beneﬁt value for high-
dose HD in-center, 5 sessions/wk.
For the probabilistic sensitivity analysis, the cost-effectiveness
plane (see Appendix Fig. I in Supplemental Materials found atLow values 
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¼ £20,000. For high-dose HD in-center (5 sessions/wk), the
anges in model parameters. Parameters that have the biggest
p of the tornado diagram, whereas those that have the least
sessions have the greatest impact on the net beneﬁt value.
nter is cost-effective vs. conventional ICHD is 0% at all values
the increased tariff, the tornado diagram (C) shows that the
of home HD. The CEAC (D) shows that the probability that
3.7% at £30,000. CEAC, cost-effectiveness acceptability curve;
is; PD, peritoneal dialysis; QALY, quality-adjusted life-year;
Table 3 – Head-to-head comparison of conventional ICHD and high-dose HD at home.
Comparative scenario analyses Total costs
(£)
QALYs ICER (vs. reference scenario)
(£)
Current home HD tariff (£456/wk)
Reference scenario: 100% conventional ICHD 191,207 5.267 –
100% high-dose HD at home 190,684 6.539 Dominant*
Reference scenario: 100% conventional ICHD, no difference in
survival
191,160 5.265 –
100% high-dose HD at home, no difference in survival 171,930 5.895 Dominant*
Increased home HD tariff (£575/wk)
Reference scenario: 100% conventional ICHD 191,256 5.267 –
100% high-dose HD at home 213,407 6.539 17,404
Reference scenario: 100% conventional ICHD, no difference in
survival
191,205 5.265 –
100% high-dose HD at home, no difference in survival 192,250 5.895 1,657
HD, hemodialysis; ICER, incremental cost-effectiveness ratio; ICHD, in-center hemodialysis; QALY, quality-adjusted life-year.
* A dominant scenario is one that is associated with higher QALYs and lower costs than the reference scenario.
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dose HD in-center falls in the upper right quadrant (i.e., more
effective and more expensive) across all 1000 model simulations;
the ICERs are all very high. Only ICER values on or below the
£20,000 per QALY WTP threshold (indicated by the sloped line in
Appendix Fig. I in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.10.002) would be considered cost-effective.
The cost-effectiveness acceptability curve results conﬁrm these
observations (Fig. 2B): at all values of the WTP threshold up
to £75,000, the probability that high-dose HD in-center is
cost-effective compared with conventional ICHD is 0%, supporting
the base-case result of an ICER of £126,106.Is High-Dose HD Cost-Effective When Performed at Home?
Using the 2013-2014 PbR home HD tariff (£456/wk), we found that
starting all patients on high-dose HD at home is associated with
lower per-patient total costs and higher QALYs (£522 and
þ£1.273, respectively) than conventional ICHD over a lifetime
(Table 3). Therefore, high-dose HD at home is dominant (asso-
ciated with better outcomes and lower costs).
Using a hypothetical home HD tariff (£575/wk) [29], we found
that the ICER for high-dose HD at home is £17,404/QALY over a
lifetime (Table 3): at the higher tariff, high- dose HD at home is
cost-effective at a WTP threshold of £20,000 to £30,000 compared
with conventional ICHD. Incremental costs and QALYs per
patient are £22,151 and 1.273, respectively.
A scenario analysis assuming equal survival for patients
receiving high-dose HD at home and conventional ICHD demon-
strated lower costs and better beneﬁts for high-dose HD at home
at the current home HD tariff. At an increased home HD tariff,
total costs per patient are slightly higher than the reference
scenario (increase of £1045 per patient) and 0.630 incremental
QALYs are accrued per patient, giving an ICER of £1657.
Sensitivity analyses for high-dose HD at home versus conven-
tional ICHD were conducted for both home HD tariffs. The weekly
tariff and the utility of home HD are the biggest drivers of results
(Fig. 2C; see Appendix Fig. II in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.10.002).
At the current home HD tariff, the cost-effectiveness plane (see
Appendix Fig. III-A in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.10.002) shows that high-dose HD at home falls
in the lower right quadrant (more effective and less expensive) for
most of the 1000 model simulations. The probability that high-dose
HD at home is cost-effective at £20,000 is 97.4% and at £30,000 is99.1% (see Appendix Fig. III-B in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.10.002).
At the increased home HD tariff, high-dose HD at home is
associated with more QALYs than is conventional ICHD (see
Appendix Fig. IV in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.10.002) across 1000 model simulations; how-
ever, more simulations fall above the £20,000 threshold line. With
the increased tariff, the probability that high-dose HD at home is
cost-effective is 61.8% at £20,000 and 83.7% at £30,000 (Fig. 2D).Discussion
We considered the effect of treating patients with high-dose HD
both in-center and at home. Differentiation was made between the
settings in terms of clinical and cost outcomes. Our analyses
demonstrate that high-dose HD is associated with better outcomes
than is conventional HD, in terms of both life-years and QALYs.
The ﬁrst base-case analysis shows that starting all patients on
high-dose in-center ICHD than on conventional ICHD is associ-
ated with higher costs and QALYs. The increase in QALYs is
attributed to both improved survival and QOL. Because the
England ICHD tariff is paid per session, higher frequency of
treatments means higher costs. The ICER for high-dose ICHD (5
sessions/wk) versus conventional ICHD (3 sessions/wk) is
£126,106, much higher than the perceived NICE WTP threshold
of £20,000 to £30,000 per QALY. Therefore, although the model
predicts that high-dose HD in-center is more effective than
conventional ICHD, costs associated with the delivery of addi-
tional HD sessions (treatment and transportation) are too high for
high-dose HD in-center to be considered cost-effective.
Results for the second base-case analysis suggest that under the
current PbR tariff (£456/wk), high-dose HD at home is associated
with lower total costs and higher QALYs than is conventional ICHD
over a lifetime; that is, high-dose HD at home is dominant.
Sensitivity analysis conﬁrmed these results. Because the introduc-
tion of the home HD tariff in 2012 has not been overly successful in
increasing the uptake of home HD, it is unlikely that it will be
sufﬁcient to increase the usage of high-dose HD at home. In line
with ICHD in which reimbursement is based on the number of
sessions, we conducted an additional analysis increasing the home
HD tariff to £575 (5 times the reference costs of one home HD
session). The resulting ICER for high-dose HD at home versus ICHD
was £17,404. Sensitivity analysis showed that at the £575/wk tariff,
high-dose HD at home has a 62% to 84% probability of being cost-
effective versus ICHD at a WTP threshold of £20,000 to £30,000 per
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would be considered cost-effective at a WTP threshold of £20,000
per QALY up to £592/wk and cost-effective up to £659/wk at a
threshold of £30,000 per QALY.
Our ﬁnding that high-dose HD in-center was not cost-effective
is consistent with a previous economic analysis that demon-
strated that within a WTP threshold lower than $75,000/QALY,
cost-effectiveness of high-dose HD in-center versus conventional
ICHD is hard to achieve [32]. Our ﬁnding that high-dose HD at
home was cost-effective is supported by a previous UK economic
analysis that reported that short-daily and nocturnal home HD
were associated with higher costs than was conventional ICHD,
largely driven by an increase in consumables required for six
sessions [9]. Both home dialysis modalities, however, were
favored over ICHD because of improved patient well-being and
likely cost savings from reduced transportation costs and hospi-
talization rates [9]. Similarly, a decision analysis examining the
cost-effectiveness of nocturnal home HD (5–7 sessions/wk) versus
conventional ICHD, over a lifecycle of ESRD, reported that higher
frequency HD was the dominant strategy, associated with higher
QALYs than in ICHD (5.79 and 5.31, respectively) and saving
approximately 1.0% of total health expenses [33].
Our results may have important implications for decision
makers. Substituting conventional ICHD with cost-effective
high-dose HD at home meets the objectives of the current NHS
Quality, Innovation, Productivity and Prevention agenda of reduc-
ing costs while improving quality of patient care [34]. Both the
National Kidney Foundation and NICE’s TA48 clinical guidelines,
however, highlight a need to raise patient awareness of the QOL
and clinical beneﬁts associated with home HD [2,35]. Too many
patients are considered unsuitable for home HD, driven by lack of
patient education and strict patient selection [36]. Although it has
been suggested that with appropriate education, 10% to 15% of
UK dialysis patients might choose home HD as a treatment
option [37], there has been no overall increase in the proportion
of patients receiving home HD. In 2012, 4% of dialysis patients in
England were receiving home HD [38].
The current analysis has several strengths. First, the model
structure was informed by previous economic evaluations in
ESRD [10,39]. Second, a thorough literature search was conducted
to identify model inputs. Third, the model was validated at a
clinical advisory board and with a UK-based nephrology key
opinion leader who had been involved in both inpatient and
outpatient NHS renal services and in NICE appraisals of HD and
PD. Although the 2013-2014 PbR dialysis tariff was used for the
analysis, the tariff represents the national average costs of
providing dialysis care in England. In addition, consistent con-
clusions were drawn using PbR dialysis tariffs since 2011-2012,
when a tariff for home HD was introduced.
The analyses have several limitations due to lack of high-quality
data. First, the utility beneﬁt assigned to high-dose HD versus
conventional ICHD was obtained from a small randomized con-
trolled trial but was varied in sensitivity analysis. Second, because
the likely QOL decrement associated with hospitalizations was not
captured, QALYsmay be overestimated. Third, for some inputs such
as survival, UK-speciﬁc data could not be sourced: we used data
from the ERA-EDTA for baseline survival and from observational
studies for survival beneﬁts of high-dose HD versus conventional
ICHD. Clinical practice in other countries may differ from that in the
United Kingdom, possibly affecting the generalization of these data
inputs to UK patients. We did, however, compare the patient
population characteristics of patients with renal disease in the
United Kingdom and Europe and conducted scenario analyses
assuming equivalent survival of high-dose HD and conventional
ICHD. ERA-EDTA (Europe) [40] registry data conﬁrmed that age and
sex distributions of patients in the United Kingdom are comparable
to those of patients in other European countries. In addition, wetested our model with a different survival methodology, in which
mortality rates from population life tables were used with adjust-
ments made to reﬂect the RRT population as published by the UK
Renal Registry [10,41]. This approach was not used for the base-case
analysis because the relative risks published are for the total RRT
population and include transplant patients. Using this approach
resulted in a lower ICER (£9042) for high-dose home HD at the
increased tariff. Fourth, data were not available to consider a HD
dose-response relationship. Data show that the 2-day interval
without dialysis is associated with increased mortality [31]; how-
ever, there is currently no conclusive evidence of the relative
effectiveness of 3.5, 5, or more dialysis sessions per week. Therefore,
in scenario analyses varying the number of sessions per week for
high-dose HD, only costs differ between scenarios. Differences in
clinical and QOL outputs are not captured. Fifth, because our
analysis used PbR tariffs to approximate costs of providing RRT to
patients with ESRD instead of microcosting, there may be scenarios
in which tariffs do not reﬂect the true costs of dialysis care,
especially when additional training is needed for some patients.
Finally, our conclusions on the cost-effectiveness of high-dose HD at
home may not be generalized to the entire UK population requiring
dialysis, including those not suitable for home dialysis due to
advancing age, associated comorbidities, and coping difﬁculties. Of
those who are suitable, some may be more appropriate for PD while
others may be more suited to home HD. Because of the lower costs
of providing PD, the cost-effectiveness of high-dose HD at home
may change signiﬁcantly when compared with patients receiving
PD. A targeted literature review identiﬁed that compared with
patients receiving PD, patients receiving home HD are generally
younger and more likely to be male [4,42–44]. Our analysis applies to
situations wherein patients prefer high-dose HD at home to PD.
Sensitivity analyses in the current study conﬁrm the base-
case results, supporting home-based high-dose HD as a preferred
strategy. To improve the reliability of economic evaluations,
however, further contemporary research is needed to strengthen
the current clinical evidence base for high-dose HD. Clinical trials
remain the criterion standard for inﬂuencing changes in clinical
practice. Given the nature of ESRD, with 50% 5-year survival,
large-scale clinical trials to assess the efﬁcacy of high-dose versus
conventional HD, however, are unlikely [32].
In conclusion, our study shows that high-dose HD is not cost-
effective when performed in-center at NICE’s WTP threshold of
£20,000 to £30,000 despite the model predicting that it is more
effective. This analysis also demonstrated that high-dose HD at
home is cost-effective versus conventional ICHD, the current
standard of care for patients with ESRD. With the number of
patients requiring dialysis rising annually in the United Kingdom,
substituting conventional ICHD with high-dose HD at home in
suitable patients could help improve patient outcomes with
reasonable increases in costs.
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